#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
Tag: metastatic breast cancer
Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...
Sacituzumab govitecan shows survival benefit in endocrine-resistant hormone-positive metastatic breast cancer
1. Median overall survival increased by 3.2 months in the sacituzumab govitecan group compared to chemotherapy. 2. One fatal treatment-related ...
Trastuzumab deruxtecan superior to physician’s choice treatment in patients with metastatic HER2-positive breast cancer
1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months). 2. Drug-related ...
Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.
1. Median progression-free survival was longer in the SG group than in the chemotherapy group. 2. Median overall survival was ...
#VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
Click to read this study in The Lancet Oncology.
Trastuzumab deruxtecan is a treatment option for pre-treated HER2-low metastatic breast cancer
1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options. ...
Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...